| __timestamp | ImmunityBio, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 305409000 |
| Thursday, January 1, 2015 | 226206000 | 377080000 |
| Friday, January 1, 2016 | 94391000 | 432829000 |
| Sunday, January 1, 2017 | 53821000 | 496079000 |
| Monday, January 1, 2018 | 35463000 | 557616000 |
| Tuesday, January 1, 2019 | 46456000 | 658498000 |
| Wednesday, January 1, 2020 | 71318000 | 770456000 |
| Friday, January 1, 2021 | 135256000 | 840100000 |
| Saturday, January 1, 2022 | 102708000 | 944700000 |
| Sunday, January 1, 2023 | 129620000 | 1136600000 |
| Monday, January 1, 2024 | 1464300000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Over the past decade, Vertex Pharmaceuticals Incorporated and ImmunityBio, Inc. have showcased contrasting strategies in optimizing these costs.
From 2014 to 2023, Vertex Pharmaceuticals consistently maintained higher SG&A expenses, peaking at approximately $1.14 billion in 2023. This reflects a strategic investment in administrative capabilities and market expansion. In contrast, ImmunityBio's SG&A expenses were significantly lower, with a peak of around $226 million in 2015, indicating a leaner operational model.
Despite ImmunityBio's lower expenses, Vertex's approach suggests a robust infrastructure supporting its growth. The data reveals a 270% increase in Vertex's SG&A expenses over the decade, compared to a 2900% increase for ImmunityBio, highlighting different growth trajectories and cost management philosophies.
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Zoetis Inc.
Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
Ionis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Rhythm Pharmaceuticals, Inc. or ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ImmunityBio, Inc.
Breaking Down SG&A Expenses: Bausch Health Companies Inc. vs ImmunityBio, Inc.